ACTRN12620000090910Completed未知
Development of less-invasive predictive biomarkers of immunotherapy treatment in patients with non-small cell lung (NSCLC) and genitourinary cancers and its impact on overall survival
Ingham Institute for Applied Medical Research0 sites48 target enrollmentStarted: February 3, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 48
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to o limit (—)
- Sex
- All
Inclusion Criteria
- •Histologically or cytologically confirmed non-small cell lung cancer, bladder cancer, kidney cancer
- •Must be commencing immunotherapy for NSCLC, renal or bladder cancer
Exclusion Criteria
- •Not commencing immunotherapy
- •No consent signed
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Prospective evaluation of non-invasive biomarkers of kidney function and musculoskeletal status with checkpoint inhibitor therapyto prospectively evaluate kidney function and musculoskeletal status in patients receiving a checkpoint inhibitor therapyDRKS00030999niversitätsmedizin Göttingen200
Completed
Not Applicable
Study for new biomarker development in the prediction of prognosis of renal function in chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000010140Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences216
Recruiting
Not Applicable
Study for new biomarker development in the prediction of prognosis of renal function in chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000014093Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences512
Completed
Not Applicable
Study for new biomarker development in the prediction of renal anemia progression in chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000008699Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences90
Recruiting
Not Applicable
Research for early detection of adverse events of immune checkpoint inhibitorsung cancerJPRN-UMIN000044022Hokkaido University of Science Faculty of Pharmaceutical Sciences25